Posts

Sanofi's Sarclisa Goes Hands-Free: Will It Matter to Physicians?

on

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

on

Eisai, Biogen scoop up subQ Leqembi starter‑dose nod – FDA greenlights subcutaneous lecanemab initiation for early Alzheimer’s disease

on

Lumvoa emerges as strong Tepezza rival—but SC Tepezza looms on the horizon

on

FDA Extends Review of LEQEMBI IQLIK Subcutaneous Starting Dose for Early Alzheimer's Disease

on

FDA Delays Decision on Sanofi's Subcutaneous Sarclisa to July 23, 2026

on

AstraZeneca Receives FDA Complete Response Letter for Subcutaneous Saphnelo in Lupus

on

Roche Bags EU Nod for SC Formulation of Lunsumio, Re-Igniting Bispecific Battle with Tepkinly

on

AstraZeneca's Saphnelo Succeeds in Phase III as Self-Injectable Lupus Treatment

on

Novo Nordisk Plans Phase 3 Trials for Next-Generation Obesity Drug Amycretin

on

Leqembi's Expansion and Blood Test Impact: Analyst Sees Gradual Uptake Boost

on

Merck's Injectable Keytruda Shows Promising Results in Pivotal Trial

on

Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735

on

FDA Approves Onapgo: Breakthrough Infusion Device for Advanced Parkinson's Disease

on